Tracy Krumme Joins Fortrea as Senior Vice President
Fortrea, a pioneering global contract research organization (CRO), has recently appointed Tracy Krumme as its new Senior Vice President of Investor Relations. This strategic move marks a significant milestone for the company as it continues to evolve within the biopharmaceutical landscape.
Transition in Leadership
In her new role, Krumme succeeds Hima Inguva, who has decided to explore different career paths after leading the company's investor relations since its inception. Chief Financial Officer Jill McConnell expressed enthusiasm about Krumme's appointment, emphasizing her extensive experience and proven track record in capital markets.
“Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter,” said McConnell. “Her deep capital markets expertise, integrity, and passion for driving transformational growth will be invaluable in helping us communicate our vision to the investment community.”
Krumme's Impressive Background
Bringing over 30 years of investor relations and capital markets experience, Krumme has worked with various organizations, enhancing their investor relations strategies. Her previous roles include heading investor relations at PPD, a prominent CRO acquired by Thermo Fisher Scientific. During her tenure, she collaborated closely with Fortrea's current CEO Anshul Thakral.
Her experience spans multiple sectors, including life sciences and healthcare, where she played pivotal roles at notable companies like Galderma and Nuance Communications. Most recently, Krumme served as Senior Vice President at Bitfarms, further enriching her understanding of diverse markets and communication strategies.
Looking Ahead
Expressing excitement about this new position, Krumme shared, “I'm thrilled to join Fortrea at such a pivotal moment in its journey as an independent, pure-play CRO. Collaborating with the leadership team, I aim to articulate Fortrea's vision and value proposition effectively to investors while providing innovative solutions to our clients.”
About Fortrea
Fortrea is recognized globally for its clinical development solutions tailored to the life sciences sector. The company collaborates with both emerging and established biopharmaceutical firms, leveraging more than three decades of expertise to enhance healthcare innovation. Specializing in phase I-IV clinical trial management, clinical pharmacology, and consulting services, Fortrea strives to accelerate life-changing therapies for patients worldwide.
The organization maintains a robust network of investigator sites across 100 countries, ensuring agile solutions focused on client needs. Fortrea's dedication to scientific rigor and exceptional insights sets it apart in the competitive CRO landscape.
Engagement and Future Aspirations
As Fortrea continues to expand its influence in the clinical research arena, the appointment of Tracy Krumme is a strategic step towards fortifying its communication with investors and stakeholders. By fostering transparent dialogues, Fortrea aims to enhance shareholder value and effectively convey its mission in leading the charge for patient-centric solutions.
Contact Information
To learn more about Fortrea, potential investors and stakeholders can reach out to:
Tracy Krumme (Investors) – 984-385-6707, tracy.krumme@fortrea.com
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
Frequently Asked Questions
Who is Tracy Krumme?
Tracy Krumme is the newly appointed Senior Vice President of Investor Relations at Fortrea, bringing over 30 years of experience in the industry.
What will Krumme's role involve?
Krumme will lead Fortrea's investor relations strategy and serve as a crucial liaison with the investment community.
What experience does Krumme have in the industry?
Krumme has extensive experience in investor relations and capital markets, holding previous positions at PPD and Bitfarms.
Why was this appointment significant?
Krumme's appointment signifies Fortrea's commitment to strengthening communication and engagement with its investors while navigating the competitive CRO landscape.
How is Fortrea regarded in the industry?
Fortrea is known as a leading global provider of clinical development solutions, focusing on innovative therapies and healthcare advancements.
